On September 19, Medytox announced that it has received product approval from the Ministry of Food and Drug Safety for "Newbeju," an injectable fat-dissolving agent indicated for the improvement of moderate to severe submental fat.
Newbeju is Medytox's first chemical new drug and is the world's first next-generation fat-dissolving injection developed with cholic acid as its main ingredient.
To maximize the fat cell destruction effect, it was optimized with an acidity (pH) similar to that of the human body. By using cholic acid as the main ingredient, it has a lower surfactant effect, which the company claims reduces side effects such as adverse reactions and pain commonly observed with deoxycholic acid (DCA) injections currently on the market.
A Medytox representative stated, "We will successfully proceed from launching in the domestic market to expanding into the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
